Opinion

The rise of DOLs doesn’t mean pharma should upend KOL approach.

Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.

Agility and better decisions depend on managing risk and gaining insights from data by prioritizing patient and end-user needs. Companies of all sizes, including GSK, Boehringer-Ingelheim, Sanofi, AstraZeneca, and AbbVie, share best practices.

New regulations may require regulators to explore new payment options.

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.

A roadmap for cohering patient perspectives.

Industry must continue research and development to combat the pandemic.

Investments setting up sector for future success that could one day rival its US counterpart.

Approval of Medicare and Medicaid coverage for digital therapeutics represents next step in advancing care for mental health patients.

Rise in demand for sustainable practices forces industry to be more proactive.

Looking to the past reminds industry of great strides taken in clinical research for patients.

Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.

How early stage can help set you up for big stage.

Continued push for latest technology in biopharma will advance collection of patient data.

Obstacles in data exchange remain for industry.

As big tech’s healthcare disruption efforts flag, biopharma can step up to empower patients and improve care, writes Rohit Gupta.

AstraZeneca’s Niko Andre discusses the power of patient partnership in driving medical progress.

Recognizing leadership in pharma.

Stay-at-home orders during the pandemic forced a shift in patient preferences—and the pharma industry has responded.

With the headlines focused on COVID-19, many may have forgotten about the escalating epidemic of substance use disorder. National Recovery Month is a time to bring this issue back to the top of the agenda, raise awareness, and drive action, writes Richard Pops, CEO of Alkermes.

What can both public and private sector stakeholders learn from current trends to accelerate innovation around the COVID-19 pandemic and other emerging global health threats, including antimicrobial resistance?

Pharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.

What are the reasons behind the slump and what does the future hold?

The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.

It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.

Ethics and diversity on full display across pharma industry.

Not to be outdone by the showbiz industry, Pharm Exec's own awards season is fast approaching.

Embracing the new, holistic views of pharma in 2021.

Mike Hennessey Sr., Chairman and Founder of MJH Life Sciences, pushes for the celebration of the pharmaceutical industry after nine grueling months of fighting COVID-19.